Clinical trials
Muscle Invasive Bladder Urothelial Carcinoma clinical trials
Below are recruiting muscle invasive bladder urothelial carcinoma clinical trials, each written for real people, not researchers. We’re tracking 113 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07265947RecruitingPhase 2
Testing dabogratinib for low-grade upper tract bladder cancer
This trial tests a new targeted therapy pill, dabogratinib, for people with low-grade upper tract urothelial carcinoma (a type of cancer in the tubes that carry urine from kidneys to bladder). It may be an option if you have tumor tissue left after a biopsy and haven't had certain prior treatments.
Tampa, FloridaAges 18 years+ - NCT05562830RecruitingPhase 1/Phase 2
Study for bladder or urinary tract cancer after PD-1 failure
This Phase 1/2 study tests investigational cancer treatment(s) in people with locally advanced or metastatic urothelial cancer that has not responded to PD-1/PD-L1 immunotherapy. It may help by trying a new approach after prior checkpoint treatment has stopped working or the cancer returns.
Orange, CaliforniaAges 18 years+ - NCT05239624RecruitingPhase 2
Enfortumab plus pembrolizumab for muscle-invasive bladder cancer
This Phase 2 study tests how well two anti-cancer medicines—enfortumab vedotin and pembrolizumab—work for people with muscle-invasive bladder cancer that has spread to nearby lymph nodes (but not distant organs). It may help shrink the cancer and improve treatment outcomes before or around planning major surgery.
Miami, FloridaAges 18 years+ - NCT04617756RecruitingPhase 2
Durvalumab plus chemo before surgery for high-risk upper urinary tract cancer
This trial studies whether durvalumab (an immunotherapy) given with chemotherapy before surgery can improve outcomes for people with high-risk cancer in the kidney pelvis or ureter. It is mainly looking at safety and effectiveness in shrinking or controlling the cancer before treatment continues.
Paris, Paris Cx 20Ages 18 years+ - NCT07321210Recruiting
Lymph node surgery for high-risk upper tract cancer
This trial compares removing the kidney and ureter alone versus also removing nearby lymph nodes for high-risk upper tract urothelial cancer. It aims to see if the extra step helps improve outcomes.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT03374267Recruiting
Urologic cancer registry study
This registry study collects information from people with different types of advanced or high-risk urologic cancers. It helps doctors learn more about how these cancers are treated in real life.
Multiple LocationsAges 18 years+ - NCT07019220RecruitingPhase 2
Chemoablation for low-risk bladder cancer
This trial tests using chemotherapy directly into the bladder to treat low-grade bladder cancer that has come back, as an alternative to surgery. It may help people with small, low-grade tumors avoid the need for a more invasive procedure.
ViennaAges 18 years+ - NCT05080998Recruiting
Tracking bladder cancer recurrence with repeated urine tests
This study follows people with past bladder cancer to see how bladder cancer comes back over time. You would provide urine samples at several visits, which helps researchers evaluate urine tests that may spot recurrence earlier.
Miami, FloridaAges 18 years+ - NCT06109857Recruiting
Bladder Bank: Collecting samples for research
This study collects urine and tissue samples from people being checked for blood in their urine (hematuria) to build a 'bladder bank' for future research. By donating samples, you help scientists learn more about bladder conditions and improve diagnosis.
Rochester, MinnesotaAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Duarte, CaliforniaAges 18 years+ - NCT06971614RecruitingPhase 2
T3011 for bladder cancer not responding to standard treatments
This trial tests a drug called T3011 for a type of bladder cancer that hasn't responded to standard treatments like BCG or chemotherapy. It aims to see if T3011 can help shrink the cancer or keep it from growing, offering a new option for people who have limited choices.
Queen Creek, ArizonaAges 18 years+ - NCT06668493RecruitingPhase 1/Phase 2
A virus-based treatment for low-grade upper tract bladder cancer
This trial tests a new drug, nadofaragene firadenovec, which uses a harmless virus to deliver a signal that helps your immune system fight low-grade cancer in the upper part of the urinary tract (the kidney area). It's given directly into the kidney through a small tube, and may avoid more invasive surgery.
Scottsdale, ArizonaAges 18 years+ - NCT07126119RecruitingPhase 2
Immunotherapy plus chemo before surgery for upper tract cancer
This trial tests whether combining the immunotherapy drug tislelizumab with the chemotherapy drug nab-paclitaxel before surgery can help treat high-risk upper tract urothelial cancer. The goal is to shrink the tumor and improve outcomes for patients who are planning to have their kidney and ureter removed.
Tianjin, Outside U.S.Ages 18 years+ - NCT04628767RecruitingPhase 2/Phase 3
Durvalumab plus chemo before surgery for upper tract cancer
This trial tests whether adding an immunotherapy drug (durvalumab) to chemotherapy before surgery can improve outcomes for people with high-grade upper tract urothelial cancer. It compares different treatment approaches based on whether a patient can receive cisplatin chemotherapy.
Kingman, ArizonaAges 18 years+ - NCT07207824RecruitingPhase 3
Study of a new drug for high-risk bladder cancer
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05394337RecruitingPhase 1/Phase 2
Immunotherapy before bladder surgery for cisplatin-ineligible patients
This trial tests two immunotherapy drugs given before bladder/urinary tract cancer surgery. It aims to shrink the tumor and improve outcomes in people who cannot safely take cisplatin chemotherapy.
Houston, TexasAges 18 years+ - NCT06892860RecruitingPhase 2
Comparing shorter vs longer chemo before immunotherapy for bladder cancer
This trial is testing whether 3 cycles of chemotherapy are as effective as 6 cycles before starting maintenance immunotherapy (avelumab) for people with advanced bladder cancer. The goal is to see if a shorter chemo course can reduce side effects while still controlling the cancer.
ParisAges 18 years+
Hear when a new Muscle Invasive Bladder Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for muscle invasive bladder urothelial carcinoma?
- Yes. Clin2 currently lists 113 recruiting muscle invasive bladder urothelial carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a muscle invasive bladder urothelial carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a muscle invasive bladder urothelial carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Non-Muscle Invasive Bladder Urothelial Carcinoma
- Muscle-Invasive Bladder Carcinoma
- Non-Muscle Invasive Bladder Carcinoma
- Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
- Recurrent Non-Muscle Invasive Bladder Carcinoma
- Non Muscle Invasive Bladder Cancer
- Urothelial Carcinoma Bladder
- Muscle Invasive Bladder Cancer (MIBC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.